HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: CJN.02190309v1 4/8/1384    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Young, B. Articles by Zaritsky, J. PubMed PubMed Citation Articles by Young, B. Articles by Zaritsky, J.

Hepcidin for Clinicians

Brian Young^*, and Joshua Zaritsky

Departments of ^* Medicine and Pediatrics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California

Correspondence: Dr. Joshua Zaritsky, A2-383 MDCC, 650 Charles Young Drive, Los Angeles, CA 90095. Phone: 310-206-6987; Fax: 310-825-0442; E-mail: jzaritsky{at}mednet.ucla.edu

Despite the use of erythropoiesis-stimulating agents (ESAs), the anemia of chronic kidney disease (CKD) can be resistant to therapy. Both absolute and functional iron deficiency along with inflammation can contribute to ESA resistance and can be difficult to identify with current-day markers of iron storage. Hepcidin, a small peptide produced by the liver, is a recently discovered key regulator of iron homeostasis. Via regulation of ferroportin, hepcidin inhibits intestinal iron absorption and iron release from macrophages and hepatocytes. Because of its renal elimination and regulation by inflammation, it is possible that progressive renal insufficiency leads to altered hepcidin metabolism, subsequently affecting enteric absorption of iron and the availability of iron stores. Thus, hepcidin likely plays a major role in the anemia of CKD as well as ESA resistance. This article discusses the biologic actions and regulation of hepcidin along with reviewing studies of hepcidin in CKD.